Gabapentin Capsule
Product Images NDC 76420-234

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 76420-234). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Asclemed Usa, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Gabapentin-300mg-cap.jpg (Gabapentin 300mg Cap)

Labels for Gabapentin Capsules, USP 300 mg, packaged by Enovachem Pharmaceuticals in various quantities: 30, 60, 90, 240, and 120 capsules. Each label includes the NDC number, barcode, distributor Ascend Laboratories LLC, prescription drug status, and storage instructions. The labels feature the Enovachem logo and packaging details from Torrance, CA.*

FDA Label Image

Gabapentin 400mg Cap

Packaging labels for Gabapentin Capsules USP 400 mg, an oral prescription drug by Enovachem Pharmaceuticals, labeled with NDCs 76420-234-30, 76420-234-60, 76420-234-90, 76420-234-24, and 76420-234-12. Each label shows package quantities of 30, 60, 90, 240, and 120 capsules respectively, listing distributor Ascend Laboratories, LLC, and a description of orange gelatin capsules in a bottle of 214 count. Labels include drug status as RX, lot and batch number placeholders, storage instructions, and a QR code.*

FDA Label Image

Gabapentin-equation (Gabapentin Equation)

A formula for calculating creatinine clearance (CLCr) is shown. It involves age in years, weight in kilograms, serum creatinine in mg/dL, and a multiplication factor of 0.85 for female patients. The formula is displayed as a mathematical expression.*

FDA Label Image

Gabapentin Fig1

A line graph displaying mean pain scores over 8 weeks for placebo and Gabapentin 3600 mg/day groups. The x-axis represents weeks, divided into a 4-week dose titration period followed by a 4-week fixed dose period. The y-axis shows mean pain scores from 0 to 10. The Gabapentin group shows a decreasing trend in pain scores compared to a relatively stable pain score in the placebo group.*

FDA Label Image

Gabapentin Fig2

A line chart depicting mean pain scores over a 7-week period comparing placebo, Gabapentin 1800 mg/day, and Gabapentin 2400 mg/day treatments. The x-axis shows weeks labeled from baseline to week 7, while the y-axis ranges from 0 to 10 representing mean pain scores. The chart indicates a 3-week dose titration period followed by a 4-week fixed dose period.*

FDA Label Image

Gabapentin Fig3

A bar graph titled 'Proportion of Responders at Endpoint: Controlled PHN Studies' depicting the percentage of patients with at least 50% reduction in pain score. It compares placebo (PBO) and Gabapentin (GBP) doses in two studies, with Study 1 showing 12% response for placebo and 29% for GBP 3600 mg, and Study 2 showing 14% for placebo, 32% for GBP 1800 mg, and 34% for GBP 2400 mg. Statistical significance is noted with p-values less than 0.01 and 0.001.*

FDA Label Image

Gabapentin-fig4 (Gabapentin Fig4)

A scatter plot chart illustrating the percentage difference (%) on the y-axis versus daily dose (mg) on the x-axis for Gabapentin capsules. Data points represent three studies labeled a, b, and c, with doses around 600 mg, 900 mg, 1200 mg, and 1800 mg. Study a uses black squares, study b gray squares, and study c white squares.*

FDA Label Image

Str Fig05

Chemical structure of gabapentin, showing its molecular framework including a cyclohexane ring and attached amino and carboxyl functional groups. The structure corresponds to the active ingredient gabapentin used in oral capsule formulations.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.